ATE526023T1 - Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes - Google Patents

Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes

Info

Publication number
ATE526023T1
ATE526023T1 AT04755763T AT04755763T ATE526023T1 AT E526023 T1 ATE526023 T1 AT E526023T1 AT 04755763 T AT04755763 T AT 04755763T AT 04755763 T AT04755763 T AT 04755763T AT E526023 T1 ATE526023 T1 AT E526023T1
Authority
AT
Austria
Prior art keywords
pyridoxamine
diabetes
treatment
type
diabetic nephropathy
Prior art date
Application number
AT04755763T
Other languages
English (en)
Inventor
Thorsten Degenhardt
Robert Schotzinger
J Fox
Original Assignee
Nephrogenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nephrogenex Inc filed Critical Nephrogenex Inc
Application granted granted Critical
Publication of ATE526023T1 publication Critical patent/ATE526023T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04755763T 2003-06-20 2004-06-18 Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes ATE526023T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48003203P 2003-06-20 2003-06-20
US56206204P 2004-04-14 2004-04-14
PCT/US2004/019808 WO2004112788A1 (en) 2003-06-20 2004-06-18 Pyridoxamine for the treatment of diabetic kidney disease

Publications (1)

Publication Number Publication Date
ATE526023T1 true ATE526023T1 (de) 2011-10-15

Family

ID=33544423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04755763T ATE526023T1 (de) 2003-06-20 2004-06-18 Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes

Country Status (10)

Country Link
US (3) US20050014799A1 (de)
EP (1) EP1643999B8 (de)
AT (1) ATE526023T1 (de)
CA (1) CA2529538C (de)
CY (1) CY1112184T1 (de)
DK (1) DK1643999T3 (de)
ES (1) ES2374399T3 (de)
PL (1) PL1643999T3 (de)
PT (1) PT1643999E (de)
WO (1) WO2004112788A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2005077902A2 (en) * 2004-02-09 2005-08-25 Biostratum, Inc. Methods for the synthesis of pyridoxamine
JPWO2006028007A1 (ja) * 2004-09-06 2008-05-08 興和株式会社 糸球体疾患治療剤
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
KR20130117658A (ko) * 2010-05-25 2013-10-28 에릭 쿠르츠 지방산의 안정한 제형
US9522884B2 (en) * 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (de) 2014-09-26 2020-10-28 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von epilepsie- und lipidstörungen
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254572A (en) 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US6740668B1 (en) * 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6716858B1 (en) * 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US6730686B1 (en) * 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US20030013746A1 (en) * 1996-09-10 2003-01-16 University Of Kansas Medical Center. Advanced glycation end-product intermediaries and post-amadori inhibition
ATE241982T1 (de) * 1998-10-22 2003-06-15 Univ South Carolina Verfahren zur hemmung von diabetischen komplikationen
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
ATE333868T1 (de) * 2000-11-02 2006-08-15 Univ South Carolina Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
US6521645B2 (en) * 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease

Also Published As

Publication number Publication date
US8067444B2 (en) 2011-11-29
US20050014799A1 (en) 2005-01-20
US20080119525A1 (en) 2008-05-22
EP1643999A1 (de) 2006-04-12
ES2374399T3 (es) 2012-02-16
CY1112184T1 (el) 2015-12-09
CA2529538C (en) 2011-04-26
EP1643999B8 (de) 2012-03-14
DK1643999T3 (da) 2012-01-02
WO2004112788A1 (en) 2004-12-29
CA2529538A1 (en) 2004-12-29
EP1643999B1 (de) 2011-09-28
PT1643999E (pt) 2012-01-09
PL1643999T3 (pl) 2012-02-29
US20060287367A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
DE602004012816D1 (de) Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen
DE602004021585D1 (de) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
TW200628168A (en) Use of organic compounds
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE502004002706D1 (de) Darreichungsform zur oralen verabreichung von wirkstoffen, vitaminen und/oder nährstoffen, kit und verwendung
CY1105105T1 (el) Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1643999

Country of ref document: EP